SE0200205D0 - Method - Google Patents

Method

Info

Publication number
SE0200205D0
SE0200205D0 SE0200205A SE0200205A SE0200205D0 SE 0200205 D0 SE0200205 D0 SE 0200205D0 SE 0200205 A SE0200205 A SE 0200205A SE 0200205 A SE0200205 A SE 0200205A SE 0200205 D0 SE0200205 D0 SE 0200205D0
Authority
SE
Sweden
Prior art keywords
hexahydroquinolin
benzonitrile
oxo
trifluoromethyl
preparing
Prior art date
Application number
SE0200205A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Jones
Jonathan Moseley
Ian Patel
Evan Snape
Maureen Young
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200205A priority Critical patent/SE0200205D0/xx
Publication of SE0200205D0 publication Critical patent/SE0200205D0/xx
Priority to KR10-2004-7011406A priority patent/KR20040077782A/ko
Priority to CNA03802764XA priority patent/CN1622938A/zh
Priority to BR0307091-3A priority patent/BR0307091A/pt
Priority to CA002473386A priority patent/CA2473386A1/en
Priority to MXPA04007055A priority patent/MXPA04007055A/es
Priority to US10/502,191 priority patent/US7012145B2/en
Priority to EP03731874A priority patent/EP1478627A1/en
Priority to JP2003562085A priority patent/JP2005520813A/ja
Priority to PCT/SE2003/000114 priority patent/WO2003062203A1/en
Priority to ZA200405860A priority patent/ZA200405860B/en
Priority to NO20043433A priority patent/NO20043433L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
SE0200205A 2002-01-24 2002-01-24 Method SE0200205D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE0200205A SE0200205D0 (sv) 2002-01-24 2002-01-24 Method
PCT/SE2003/000114 WO2003062203A1 (en) 2002-01-24 2003-01-23 Method
CA002473386A CA2473386A1 (en) 2002-01-24 2003-01-23 Method
CNA03802764XA CN1622938A (zh) 2002-01-24 2003-01-23 方法
BR0307091-3A BR0307091A (pt) 2002-01-24 2003-01-23 Método para produzir um composto, composto, uso do mesmo, composição farmacêutica, e, método para tratar uma doença ou condição que resulte de ativação inapropriada do músculo liso
KR10-2004-7011406A KR20040077782A (ko) 2002-01-24 2003-01-23 방법
MXPA04007055A MXPA04007055A (es) 2002-01-24 2003-01-23 Metodo.
US10/502,191 US7012145B2 (en) 2002-01-24 2003-01-23 Method
EP03731874A EP1478627A1 (en) 2002-01-24 2003-01-23 Method
JP2003562085A JP2005520813A (ja) 2002-01-24 2003-01-23 方法
ZA200405860A ZA200405860B (en) 2002-01-24 2004-07-22 Method.
NO20043433A NO20043433L (no) 2002-01-24 2004-08-17 Fremgangsmate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200205A SE0200205D0 (sv) 2002-01-24 2002-01-24 Method

Publications (1)

Publication Number Publication Date
SE0200205D0 true SE0200205D0 (sv) 2002-01-24

Family

ID=20286758

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200205A SE0200205D0 (sv) 2002-01-24 2002-01-24 Method

Country Status (12)

Country Link
US (1) US7012145B2 (xx)
EP (1) EP1478627A1 (xx)
JP (1) JP2005520813A (xx)
KR (1) KR20040077782A (xx)
CN (1) CN1622938A (xx)
BR (1) BR0307091A (xx)
CA (1) CA2473386A1 (xx)
MX (1) MXPA04007055A (xx)
NO (1) NO20043433L (xx)
SE (1) SE0200205D0 (xx)
WO (1) WO2003062203A1 (xx)
ZA (1) ZA200405860B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065842A2 (en) * 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
GB9407432D0 (en) * 1994-04-14 1994-06-08 Zeneca Ltd Heterocyclic derivative
US7074931B2 (en) * 2000-08-02 2006-07-11 Astrazeneca Ab Process for asymmetric synthesis of substituted 1,4 -dihydropyridines

Also Published As

Publication number Publication date
CA2473386A1 (en) 2003-07-31
MXPA04007055A (es) 2004-10-11
US7012145B2 (en) 2006-03-14
JP2005520813A (ja) 2005-07-14
ZA200405860B (en) 2005-08-15
KR20040077782A (ko) 2004-09-06
EP1478627A1 (en) 2004-11-24
WO2003062203A1 (en) 2003-07-31
CN1622938A (zh) 2005-06-01
US20050080104A1 (en) 2005-04-14
BR0307091A (pt) 2004-12-28
NO20043433L (no) 2004-08-17

Similar Documents

Publication Publication Date Title
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
EG24978A (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment.
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
MY136520A (en) Novel compounds
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE494884T1 (de) Oxidative zusammensetzung zur behandlung von keratinfasern, die spezielle aminosilikone enthält
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
YU13301A (sh) Muskarinski agonisti i antagonisti
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
TW200502234A (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
DE10190485T1 (de) Verfahren zur Herstellung von 5-Cyano-1-(4-fluorphenyl)-1,3-dihydroisobenzofuranen
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
SE0200843D0 (sv) Chemical compounds
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
PL373192A1 (en) Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
MXPA04005151A (es) Compuestos terapeuticos.
SE0200205D0 (sv) Method
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen